• If you are wondering whether AbbVie at around US$227.45 is still offering value after a strong multi year run, this article walks through what the numbers actually say about its valuation.
• The stock has seen mixed recent returns, with a 2.9% decline over the last 7 days, a 1.8% gain over 30 days, a 0.8% decline year to date, and a 1 year return of 8.5% on top of very large 3 year and 5 year gains of 66.8% and 149.8% respectively.
• Recent headlines around AbbVie have focused on its position as a large pharmaceuticals player and ongoing interest in its product portfolio and pipeline, which help frame how investors think about future cash flows and risk. These themes often influence how the market prices the stock, especially after such strong multi year returns.
• Right now AbbVie scores 2 out of 6 on Simply Wall St's valuation checks, indicating it screens as undervalued on two metrics. We will look at what that means using several valuation approaches before finishing with an even more complete way to think about what the stock is really worth.

AbbVie scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: AbbVie Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts those back to today to estimate what the business might be worth right now. It is effectively asking what future cash the company could generate in today’s dollars.

For AbbVie, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve months free cash flow sits at about $18.0b. Analyst based and extrapolated estimates suggest free cash flow could be around $31.5b by 2030, with a series of annual projections in between that are discounted back to today.

Pulling all of those projected cash flows together, Simply Wall St’s DCF model arrives at an estimated intrinsic value of about $370.71 per share. Compared with the current share price of around $227.45, the model implies AbbVie trades at roughly a 38.6% discount to its DCF estimate, so on this measure the stock screens as undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests AbbVie is undervalued by 38.6%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: AbbVie Price vs Earnings

For a profitable company like AbbVie, the P/E ratio is a useful yardstick because it links what you pay per share to the earnings the business is currently generating. Investors usually accept a higher P/E when they expect stronger growth or see lower risk, and a lower P/E when growth expectations are more modest or risks feel higher.

AbbVie currently trades on a P/E of about 96.08x. That sits well above the Biotechs industry average of 21.37x and the peer average of 23.79x. On simple comparisons, the shares look expensive relative to both the wider industry and closer peers.

Simply Wall St’s Fair Ratio tries to improve on those basic comparisons. It estimates what AbbVie’s P/E could be given factors such as its earnings growth profile, industry, profit margins, market cap and company specific risks. For AbbVie, this Fair Ratio is 38.66x, which is higher than the industry and peer averages but still well below the current 96.08x.

The gap between AbbVie’s Fair Ratio of 38.66x and its actual P/E of 96.08x suggests the shares screen as overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your AbbVie Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple tool on Simply Wall St’s Community page that lets you connect your view of AbbVie’s story to a set of revenue, earnings and margin forecasts. You can then turn that into a fair value, compare it with the current price to decide whether the stock looks cheap or expensive for you, and see that view refresh as new earnings or news arrive. For example, one user might build a bullish AbbVie Narrative with a fair value near US$372.03 based on strong immunology and pipeline expectations, while another might take a more cautious stance closer to the US$170 analyst bear case. Both can clearly see how their different stories translate into different fair values and decisions.

Do you think there's more to the story for AbbVie? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.